Josh Hardman

Josh Hardman founded Psychedelic Alpha in the spring of 2020. Having studied at the London School of Economics and UC Berkeley, Josh spent several years working in economic policy, advising startups and following the early days of the so-called ‘psychedelic renaissance’ very closely.

Through Psychedelic Alpha, Josh has authored hundreds of analyses on topics broadly related to psychedelic business, policy and research (e.g., drug development, IP, commercialisation, regulation, investment). He has also worked on both the investor (first at a venture fund, presently as an Advisor to investors and VCs) and operator side (as founder of Psychedelic Alpha and Advisor to several companies) of the industry.

He has spoken about psychedelic drug development and industry at conferences including SXSW, Horizons, and SOCAP Global; and has acted as an expert witness at meetings held by bodies such as the European Parliament and the U.S. Department of Health and Human Services. He has lectured on psychedelic drug development at institutions such as the University of Wisconsin-Madison.

Josh is fortunate to be surrounded and informed by a network of experts and advisors: from lawyers and patent attorneys to neuropsychopharmacologists and institutional investors.